BioSpace News Archive

CONMED Corporation announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference at 10:00 a.m. ET on Thursday, June 8, 2023.

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company is working with its U.S distributor network

Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology Annual Meeting, taking place from June 2-6, 2023.

Structure Therapeutics Inc. announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus who are overweight or obese.

Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.

Takeda and HUTCHMED Limited announced that the U.S. Food and Drug Administration has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib in patients with ER+ metastatic breast cancer.

Evaxion Biotech A/S to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois.

Evaxion Biotech A/S unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.